Role of angiotensin II in cardiovascular disease - Therapeutic implications of more than a century of research

被引：179

作者：

Ferrario, CM ^{[1
]}

机构：

[1] Wake Forest Univ, Bowman Gray Sch Med, Hypertens & Vasc Dis Ctr, Winston Salem, NC 27157 USA

来源：

JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM | 2006年 / 7卷 / 01期

关键词：

hypertension; cardiovascular disease; diabetes mellitus; angiotensin II antagonists; ACE inhibitors; stroke; heart failure; post myocardial infarction; diabetic nephropathy;

D O I：

10.3317/jraas.2006.003

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

More than a century of research on the renin-angiotensin system (RAS) has uncovered the widespread involvement of angiotensin II (Ang II) in the pathophysiology of cardiovascular diseases. A number of outcomes-based mega trials utilising hard clinical endpoints have revealed beneficial effects of angiotensin receptor antagonists (AIIAs/ARBs) in patients with hypertension, heart failure, diabetic nephropathy, and post-myocardial infarction (MI). The results of these studies not only emphasise the importance of Ang 11 in the pathophysiology of these diseases but have provided the basis for an evidence-based approach for the use of AIIAs in clinical practice. It is hoped that the next 100 years of research into the RAS will uncover hitherto unimaginable therapeutic opportunities.

引用

页码：3 / 14

页数：12

共 36 条

[1] Plasma renin activity: A risk factor for myocardial infarction in hypertensive patients [J].

Alderman, MH ;

Ooi, WL ;

Cohen, H ;

Madhavan, S ;

Sealey, JE ;

Laragh, JH .

AMERICAN JOURNAL OF HYPERTENSION, 1997, 10 (01) :1-8

[2] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].

Brenner, BM ;

Cooper, ME ;

de Zeeuw, D ;

Keane, WF ;

Mitch, WE ;

Parving, HH ;

Remuzzi, G ;

Snapinn, SM ;

Zhang, ZX ;

Shahinfar, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869

[3] Atenolol in hypertension: is it a wise choice? [J].

Carlberg, B ;

Samuelsson, O ;

Lindholm, LJ .

LANCET, 2004, 364 (9446) :1684-1689

[4] A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure [J].

Cohn, JN ;

Tognoni, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) :1667-1675

[5] Population impact of losartan use on stroke in the European Union (EU):: Projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study [J].

Dahlöf, B ;

Burke, TA ;

Krobot, K ;

Carides, GW ;

Edelman, JM ;

Devereux, RB ;

Diener, HC .

JOURNAL OF HUMAN HYPERTENSION, 2004, 18 (06) :367-373

[6] Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].

Dahlöf, B ;

Devereux, RB ;

Kjeldsen, SE ;

Julius, S ;

Beevers, G ;

de Faire, U ;

Fyhrquist, F ;

Ibsen, H ;

Kristiansson, K ;

Lederballe-Pedersen, O ;

Lindholm, LH ;

Nieminen, MS ;

Omvik, P ;

Oparil, S ;

Wedel, H .

LANCET, 2002, 359 (9311) :995-1003

[7] Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol -: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial [J].

Devereux, RB ;

Dahlöf, B ;

Gerdts, E ;

Boman, K ;

Nieminen, MS ;

Papademetriou, V ;

Rokkedal, J ;

Harris, KE ;

Edelman, JM ;

Wachtell, K .

CIRCULATION, 2004, 110 (11) :1456-1462

[8] Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAL randomised trial [J].

Dickstein, K ;

Kjekshus, J .

LANCET, 2002, 360 (9335) :752-760

[9]

EDELMAN JM, 2004, ANN INTERN MED, V140, pW29

[10]

Ferrario CM, 2004, CELL MOL LIFE SCI, V61, P2720, DOI 10.1007/s00018-004-4243-4

← 1 2 3 4 →